[1,3]oxazolo[5,4-c]pyridine-6-carboxylic acid | 478169-55-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶唑并吡啶类
• 英文名称: [1,3]oxazolo[5,4-c]pyridine-6-carboxylic acid
• 英文别名: Oxazolo[5,4-C]pyridine-6-carboxylic acid
• CAS: 478169-55-0
• 化学式: C₇H₄N₂O₃
• 分子量: 164.12
• InChiKey: MKAOHTDCRKTSMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease
  申请人：——

  公开号：US20030073707A1

  公开（公告）日：2003-04-17

  The invention provides compounds of Formula I: 1 wherein W 0 is a bicyclic moiety and is 2 These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful to treat diseases or conditions in which &agr;7 is known to be involved.

  这项发明提供了Formula I的化合物： 其中W0是一个双环基团，是 这些化合物可以是药物盐或组合物的形式，可以是纯对映体形式或混合物，对治疗已知涉及α7的疾病或症状有用。
• [EN] PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES<br/>[FR] DERIVES AZABICYCLIQUES DE PYRIDYLOXYMETHYL ET DE BENZISOXAZOLE
  申请人：PFIZER PROD INC

  公开号：WO2004081007A1

  公开（公告）日：2004-09-23

  An aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound according to formula (I) a pharmaceutical composition comprising same, and a method of treating one or more CNS or other disorders, including concurrent treatment of disorders such as chizophrenia and depression. Or the (R) or (S) enantiomer thereof, or the cis or trans isomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or of any of the foregoing, wherein m is 0 or 1, Z is wherein R7 is hydrogen or (C1-C3)alkoxy; R8 is hydrogen, hydroxy, or (C1-C3)alkoxy; and R9 is (C1-C3)alkoxy; X is oxygen or NR, wherein R is hydrogen or (C1-C6)alkyl; Y is methylene, wherein n is 0, 1 or 2; or oxygen, nitrogen or sulfur, wherein n is 2, 3 or 4; R1 and R2 are each independently hydrogen, halogen, or a (C1-C6)alkyl, (C1-C6)alkoxy or a (C1-C6)alkoxy(C1-C6)alkyl group, any one of which groups may be unsbustituted or substituted with one or more halogens.

  根据公式（I），一种含有氨甲基吡啶氧甲基/苯并异噁唑取代的氮杂环化合物，包括相同的药物组合物，以及治疗一种或多种中枢神经系统或其他疾病的方法，包括同时治疗精神分裂症和抑郁症等疾病。或其（R）或（S）对映体，或其顺式或反式异构体，或其药用可接受的盐、溶剂化合物或前药，或前述任何一种，其中m为0或1，Z为其中R7为氢或（C1-C3）烷氧基；R8为氢、羟基或（C1-C3）烷氧基；R9为（C1-C3）烷氧基；X为氧或NR，其中R为氢或（C1-C6）烷基；Y为亚甲基，其中n为0、1或2；或氧、氮或硫，其中n为2、3或4；R1和R2各自独立地为氢、卤素或（C1-C6）烷基，（C1-C6）烷氧基或（C1-C6）烷氧基（C1-C6）烷基基团，其中任何一个基团可以未被取代或被一个或多个卤素取代。
• [EN] N-AZABICYCLO-SUBSTITUTED HETERO-BICYCLIC CARBOXAMIDES AS NACHR AGONISTS<br/>[FR] CARBOXAMIDES HETERO-BICYCLIQUES SUBSTITUES PAR N-AZABICYCLO, UTILISES EN TANT QU'AGONISTES DU RECEPTEUR DE L'ACETYLCHOLINE NICOTINIQUE
  申请人：UPJOHN CO

  公开号：WO2003037896A1

  公开（公告）日：2003-05-08

  The invention provides compounds of Formula (I), wherein Azabicyclo is I, II, III, IV, V, or VI; W0 is a bicyclic moiety and is (a), (b) or (c). These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which α7 is known to be involved.

  本发明提供式(I)的化合物，其中Azabicyclo为I、II、III、IV、V或VI；W0为双环基团，可为(a)、(b)或(c)。这些化合物可以是药物盐或组合物的形式，可以是纯对映体形式或混合物形式，并且在已知α7参与的药物中是有用的。
• Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds
  申请人：Corbett W. Jeffrey

  公开号：US20050245504A1

  公开（公告）日：2005-11-03

  The present invention relates to compositions and methods to treat diseases or condition with an α7 nAChR full agonist and an inhibitor of cholinesterase, and or beta secretase and or gamma secretase.

  本发明涉及利用α7 nAChR全激动剂和胆碱酯酶抑制剂，和/或beta秘鲁和/或gamma秘鲁的组合物和方法来治疗疾病或症状。
• N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
  申请人：——

  公开号：US20030176702A1

  公开（公告）日：2003-09-18

  The invention provides compounds of Formula I: 1 wherein Azabicyclo is 2 W 0 is a bicyclic moiety and is 3 These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which &agr;7 is known to be involved.

  本发明提供了I式化合物：1其中Azabicyclo是2W0是一个双环基团，是3这些化合物可以是药物盐或组合物的形式，可以是纯对映体形式或混合物，适用于已知涉及α7的药物中。